INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 411m ago
HOUSE PTR11m ago
SEC 13F11m ago
ROBINHOOD CHAIN11m ago
Corporate insider
CE

Cowan Elvia

SVP, Finance & CAOCIK 0001960048

EDGAR filingsOpen in network
Disclosed transactions22
Buys / sells0 / 9
Max Insider Score46
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
0
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Option exercise · 10b5-1 plan
M—
3,000 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Vaxcyte, Inc.SVP, FINANCE · Dec 29, 2025
3
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Open-market sale · 10b5-1 plan
SELL
$36K
586 sh
Nov 2, 2026
Nov 4, 2026
traded Nov 2, 2026
+2d
SEC FORM 4

Evidence

10
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Open-market sale · 10b5-1 plan
SELL$147K
2,414 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

0
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Option exercise · 10b5-1 plan
M$78K
3,000 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

20
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Open-market sale · 10b5-1 plan
SELL$1.65M
19.0K sh
Oct 5, 2026Oct 7, 2026
traded Oct 5, 2026
+2dSEC FORM 4

Evidence

0
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Option exercise · 10b5-1 plan
M—
19.0K sh
Oct 5, 2026Oct 7, 2026
traded Oct 5, 2026
+2dSEC FORM 4

Evidence

10
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Option exercise · 10b5-1 plan
M$492K
19.0K sh
Oct 5, 2026Oct 7, 2026
traded Oct 5, 2026
+2dSEC FORM 4

Evidence

9
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Tax withholding
F$80K
1,327 sh
Sep 8, 2026Sep 9, 2026
traded Sep 8, 2026
+1dSEC FORM 4

Evidence

2
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Tax withholding
F$15K
243 sh
Aug 31, 2026Sep 2, 2026
traded Aug 31, 2026
+2dSEC FORM 4

Evidence

2
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Tax withholding
F$20K
326 sh
Sep 2, 2026Sep 2, 2026
traded Sep 2, 2026
+0dSEC FORM 4

Evidence

8
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Open-market sale · 10b5-1 plan
SELL$180K
3,000 sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

2
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Option exercise · 10b5-1 plan
M$78K
3,000 sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

0
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Option exercise · 10b5-1 plan
M—
3,000 sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

1
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Open-market sale · 10b5-1 plan
SELL$23K
405 sh
Mar 17, 2026Mar 18, 2026
traded Mar 17, 2026
+1dSEC FORM 4

Evidence

4
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Open-market sale · 10b5-1 plan
SELL$82K
1,487 sh
Mar 17, 2026Mar 18, 2026
traded Mar 17, 2026
+1dSEC FORM 4

Evidence

2
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Option exercise · 10b5-1 plan
M$65K
2,500 sh
Mar 11, 2026Mar 11, 2026
traded Mar 11, 2026
+0dSEC FORM 4

Evidence

8
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Open-market sale · 10b5-1 plan
SELL$146K
2,500 sh
Mar 11, 2026Mar 11, 2026
traded Mar 11, 2026
+0dSEC FORM 4

Evidence

0
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Option exercise · 10b5-1 plan
M—
2,500 sh
Mar 11, 2026Mar 11, 2026
traded Mar 11, 2026
+0dSEC FORM 4

Evidence

0
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Tax withholding · 10b5-1 plan
F$29K
495 sh
Mar 9, 2026Mar 11, 2026
traded Mar 9, 2026
+2dSEC FORM 4

Evidence

22
CE
Cowan ElviaSVP, FINANCE
PCVXVaxcyte, Inc.
Gift
G—
1,000 sh
Dec 23, 2025Dec 29, 2025
traded Dec 23, 2025
+6dSEC FORM 4

Evidence

39
CE
Cowan ElviaSVP, FINANCE
PCVXVaxcyte, Inc.
Open-market sale
SELL$235K
4,907 sh
Dec 23, 2025Dec 29, 2025
traded Dec 23, 2025
+6dSEC FORM 4

Evidence

46
CE
Cowan ElviaSVP, FINANCE
PCVXVaxcyte, Inc.
Open-market sale
SELL$322K
6,716 sh
Dec 23, 2025Dec 29, 2025
traded Dec 23, 2025
+6dSEC FORM 4

Evidence